Company profile for Dogwood Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Dogwood Therapeutics is a biotechnology company focused on developing novel treatments for pain and fatigue-related illnesses. Their lead candidate, Halneuron®, is a sodium channel blocker targeting chemotherapy-induced neuropathic pain (CINP) and other severe pain conditions. Additionally, they are pioneering antiviral combination therapies to treat diseases like Long COVID and fibromyalgia, which are linked to abnormal immu...
Dogwood Therapeutics is a biotechnology company focused on developing novel treatments for pain and fatigue-related illnesses. Their lead candidate, Halneuron®, is a sodium channel blocker targeting chemotherapy-induced neuropathic pain (CINP) and other severe pain conditions. Additionally, they are pioneering antiviral combination therapies to treat diseases like Long COVID and fibromyalgia, which are linked to abnormal immune responses triggered by viruses. Dogwood emphasizes non-opioid pain management solutions with minimal side effects, aiming to address significant unmet medical needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
44 Milton Avenue Alpharetta, GA 30009
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-11-11/dogwood-announces-enrollment-of-first-100-patients-in-ongoing-halneuron-r-phase-2b-trial-interim-s

PHARMIWEB
11 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3182625/0/en/Dogwood-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
06 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-30/dogwood-therapeutics-to-report-third-quarter-2025-financial-results-on-thursday-november-6-2025

PHARMIWEB
30 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-14/dogwood-therapeutics-to-participate-at-the-maxim-growth-summit-2025

PHARMIWEB
14 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-07/dogwood-therapeutics-inc-chief-medical-officer-dr-michael-gendreau-to-present-an-overview-of-th

PHARMIWEB
07 Oct 2025

https://www.globenewswire.com/news-release/2025/09/29/3157595/0/en/Dogwood-Therapeutics-Secures-Exclusive-Worldwide-Royalty-Free-License-to-Develop-and-Commercialize-SP16-as-a-Treatment-for-Cancer-Related-Pain-in-an-All-Stock-Transaction-Underscor.html

GLOBENEWSWIRE
29 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty